A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Summary

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.

Timeline

Start

2023-09-22

Primary completion

2025-09-15

Completion

2027-10-31

Drugs

Indications